These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

7409 related articles for article (PubMed ID: 2977965)

  • 1. [Cryotherapy of metastatic B16 melanoma. Consequences of the immunogenic potential].
    Bellangeon M; Hosni M; Tétu A; Santini R; Pacheco H
    C R Seances Soc Biol Fil; 1988; 182(5):453-7. PubMed ID: 2977965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Immunogenicity of 2 murine B16 melanoma variants with high metastatic potential].
    Hosni M; Santini R; Deschaux P; Pacheco H
    C R Seances Soc Biol Fil; 1990; 184(1):47-54. PubMed ID: 2150781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dendritic cell-based genetic immunization in mice with a recombinant adenovirus encoding murine TRP2 induces effective anti-melanoma immunity.
    Tüting T; Steitz J; Brück J; Gambotto A; Steinbrink K; DeLeo AB; Robbins P; Knop J; Enk AH
    J Gene Med; 1999; 1(6):400-6. PubMed ID: 10753065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of immunogenic B16 melanoma-associated antigens.
    Johnston D; Schachne JP; Bystryn JC
    J Biol Response Mod; 1987 Apr; 6(2):108-20. PubMed ID: 3585408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Demonstration of immunogenicity with the poorly immunogenic B16 melanoma.
    Celik C; Lewis DA; Goldrosen MH
    Cancer Res; 1983 Aug; 43(8):3507-10. PubMed ID: 6861123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extraction of immunogenic and suppressogenic antigens from variants of B16 melanoma exhibiting low or high metastatic potentials.
    LeGrue SJ; Hearn DR
    Cancer Res; 1983 Nov; 43(11):5106-11. PubMed ID: 6616449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The designer cytokine hyper-IL-6 mediates growth inhibition and GM-CSF-dependent rejection of B16 melanoma cells.
    Ozbek S; Peters M; Breuhahn K; Mann A; Blessing M; Fischer M; Schirmacher P; Mackiewicz A; Rose-John S
    Oncogene; 2001 Feb; 20(8):972-9. PubMed ID: 11314032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunization of mice with irradiated melanoma tumor cells transfected to secrete lymphokines and coupled with IL-2 or GM-CSF therapy.
    Shrayer DP; Bogaars H; Hearing VJ; Wanebo HJ
    J Exp Ther Oncol; 1996 Mar; 1(2):126-33. PubMed ID: 9414396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The mechanism of anti-tumor immune response against mouse melanoma to xenogeneic vaccination].
    Luo F; Mao YQ; Kan B; He QM; Jiang Y; Peng F; Yang L; Tian L
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Nov; 35(6):757-60. PubMed ID: 15573746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new mouse model of experimental melanoma for vaccine and lymphokine therapy.
    Shrayer DP; Bogaars H; Wolf SF; Hearing VJ; Wanebo HJ
    Int J Oncol; 1998 Aug; 13(2):361-74. PubMed ID: 9664134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Xenogeneic melanoma-related antigen elicits anti-tumor immune response, companied by autoimmune injury].
    Tan XH; Wan YH
    Zhonghua Yi Xue Za Zhi; 2005 Jun; 85(23):1596-600. PubMed ID: 16185524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of irradiation on cytokine production, MHC antigen expression, and vaccine potential of interleukin-2 and interferon-gamma gene-modified melanoma cells.
    Abdel-Wahab Z; Dar MM; Hester D; Vervaert C; Gangavalli R; Barber J; Darrow TL; Seigler HF
    Cell Immunol; 1996 Aug; 171(2):246-54. PubMed ID: 8806794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccination with B16 melanoma cells expressing a secreted form of interleukin-1beta induces tumor growth inhibition and an enhanced immunity against the wild-type B16 tumor.
    Björkdahl O; Dohlsten M; Sjögren HO
    Cancer Gene Ther; 2000 Oct; 7(10):1365-74. PubMed ID: 11059695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Interleukin-12 gene transfection into murine B16 melanoma cells suppresses tumorigenicity and decreases metastatic potential].
    Fu J; Zheng J; Fang W
    Zhonghua Yi Xue Za Zhi; 1998 Aug; 78(8):627-9. PubMed ID: 11038817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complete antitumor protection by perioperative immunization with GM3/VSSP vaccine in a preclinical mouse melanoma model.
    Gabri MR; Mazorra Z; Ripoll GV; Mesa C; Fernandez LE; Gomez DE; Alonso DF
    Clin Cancer Res; 2006 Dec; 12(23):7092-8. PubMed ID: 17145833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A unique tumor rejection antigen from the S91 murine malignant melanoma.
    Law LW; Vieira WD; Kameyama K; Hearing VJ
    Cancer Res; 1987 Nov; 47(22):5841-5. PubMed ID: 3664485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
    Wang J; Saffold S; Cao X; Krauss J; Chen W
    J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-tumor effect of splenocytes treated with RNA from animals immunized with bovine myelin basic protein.
    Watanabe MA; De Lucca FL
    Cell Mol Biol (Noisy-le-grand); 1996 Mar; 42(2):249-54. PubMed ID: 8696262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunostimulatory neem leaf preparation acts as an adjuvant to enhance the efficacy of poorly immunogenic B16 melanoma surface antigen vaccine.
    Baral R; Mandal I; Chattopadhyay U
    Int Immunopharmacol; 2005 Jul; 5(7-8):1343-52. PubMed ID: 15914339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma.
    Oniki S; Nagai H; Horikawa T; Furukawa J; Belladonna ML; Yoshimoto T; Hara I; Nishigori C
    Cancer Res; 2006 Jun; 66(12):6395-404. PubMed ID: 16778218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 371.